Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Financing Activities (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Cash from Financing Activities for 4 consecutive years, with $471000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 74.55% to $471000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 99.4% year-over-year, with the annual reading at $1.2 million for FY2025, 99.4% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $471000.0 at Day One Biopharmaceuticals, down from $748000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $200.1 million in Q3 2024, with the low at $48000.0 in Q1 2024.
  • Average Cash from Financing Activities over 4 years is $41.1 million, with a median of $1.3 million recorded in 2024.
  • Peak annual rise in Cash from Financing Activities hit 173895.65% in 2024, while the deepest fall reached 99.2% in 2024.
  • Over 4 years, Cash from Financing Activities stood at $1.9 million in 2022, then crashed by 68.87% to $597000.0 in 2023, then soared by 210.05% to $1.9 million in 2024, then crashed by 74.55% to $471000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $471000.0, $748000.0, and $1.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.